Ocean Biomedical Stock Performance
| OCEA Stock | 0.71 0.02 2.74% |
The company holds a Beta of 0.39, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Ocean Biomedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ocean Biomedical is expected to be smaller as well. At this point, Ocean Biomedical has a negative expected return of -0.63%. Please make sure to check Ocean Biomedical's value at risk, accumulation distribution, and the relationship between the treynor ratio and skewness , to decide if Ocean Biomedical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ocean Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Ocean Biomedical, Inc. Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Abili... | 10/01/2024 |
2 | Ocean Biomedical secures 22 percent Virion stake with 9 million deal - Investing.com | 10/17/2024 |
3 | Ocean Biomedical receives notice from Nasdaq regarding late filing | 11/22/2024 |
| Begin Period Cash Flow | 1.1 M |
Ocean |
Ocean Biomedical Relative Risk vs. Return Landscape
If you would invest 113.00 in Ocean Biomedical on August 30, 2024 and sell it today you would lose (42.00) from holding Ocean Biomedical or give up 37.17% of portfolio value over 90 days. Ocean Biomedical is currently does not generate positive expected returns and assumes 4.4009% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Ocean, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ocean Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ocean Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ocean Biomedical, and traders can use it to determine the average amount a Ocean Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1435
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OCEA |
Estimated Market Risk
| 4.4 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ocean Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ocean Biomedical by adding Ocean Biomedical to a well-diversified portfolio.
Ocean Biomedical Fundamentals Growth
Ocean Stock prices reflect investors' perceptions of the future prospects and financial health of Ocean Biomedical, and Ocean Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ocean Stock performance.
| Return On Asset | -6.82 | ||||
| Current Valuation | 36.96 M | ||||
| Shares Outstanding | 34.65 M | ||||
| Price To Book | 100.67 X | ||||
| EBITDA | (957.74 K) | ||||
| Net Income | (958.43 K) | ||||
| Total Debt | 2.15 M | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | (747.3 K) | ||||
| Earnings Per Share | (3.00) X | ||||
| Market Capitalization | 25.64 M | ||||
| Total Asset | 110.91 M | ||||
| Retained Earnings | (2.77 M) | ||||
| Working Capital | (3 M) | ||||
About Ocean Biomedical Performance
By analyzing Ocean Biomedical's fundamental ratios, stakeholders can gain valuable insights into Ocean Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ocean Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ocean Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Ocean Biomedical performance evaluation
Checking the ongoing alerts about Ocean Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ocean Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ocean Biomedical generated a negative expected return over the last 90 days | |
| Ocean Biomedical has some characteristics of a very speculative penny stock | |
| Ocean Biomedical has high historical volatility and very poor performance | |
| Net Loss for the year was (958.43 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ocean Biomedical generates negative cash flow from operations | |
| Ocean Biomedical has a poor financial position based on the latest SEC disclosures | |
| About 72.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: Ocean Biomedical receives notice from Nasdaq regarding late filing |
- Analyzing Ocean Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ocean Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Ocean Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ocean Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ocean Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ocean Biomedical's stock. These opinions can provide insight into Ocean Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ocean Stock analysis
When running Ocean Biomedical's price analysis, check to measure Ocean Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocean Biomedical is operating at the current time. Most of Ocean Biomedical's value examination focuses on studying past and present price action to predict the probability of Ocean Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocean Biomedical's price. Additionally, you may evaluate how the addition of Ocean Biomedical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |